Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nortran Pharmaceutical -NRT.V -- Ignore unavailable to you. Want to Upgrade?

To: Wisee who wrote (640)	5/10/1998 11:07:00 PM
From: SOROS	Read Replies (1) \| Respond to of 1185

That is what I would like to know. What other small biotech companies have gotten this kind of a deal from a company as large as LaRoche and what were the outcomes? Surely, everyone has to agree that a lot of the uncertainty an investor has with biotechs has been alleviated by Hoffmann-LaRoche. Also, why is this deal not as good or better than the Forbes Medi-Tech, and why should Nortran's share price not equal theirs? Answers anyone? I remain, SOROS

To: Wisee who wrote (640)	5/10/1998 11:26:00 PM
From: Mr. Forthright	Read Replies (2) \| Respond to of 1185

The ultimate success of this company will come from the success of the trials which should take 3 to 6 years and the potential market for the drugs if they work, not an investment from a large pharmaceutical company. The deal with Hoffman is done and the promotion based on the whisper campaign brought the stock to where it is now. What's next? Biotech companies while going through clinical trials often don't have much to release which is what drives these companies prior to the earnings phase. The Hoffman endorsement is great but how long can the promoters keep the stock going on the back of that news? And how high will they take it? The biotech field is full of companies that spent millions on drugs that never got approved. Mr Jay Abella, can you give us an overview of the company's plans with respect to the clinical trials (including the timing, size and protocols of these trials) and the market potential of the drugs. A quantitative analysis based on discounted future cash flows would seem appropriate. Thanks for you help.